Who are Vyndamax (tafamidis 61mg)'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vyndamax-tafamidis-61mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vyndamax (tafamidis 61mg) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vyndamax (tafamidis 61mg) (vyndamax-tafamidis-61mg) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: As prescribed in real world practice. Area: Cardiovascular.

preclinical As prescribed in real world practice Cardiovascular Live · refreshed every 30 min

Target snapshot

Vyndamax (tafamidis 61mg) (vyndamax-tafamidis-61mg) — Pfizer Inc.. As prescribed in real world practice

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vyndamax (tafamidis 61mg) TARGET	vyndamax-tafamidis-61mg	Pfizer Inc.	preclinical	As prescribed in real world practice

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (As prescribed in real world practice class)

Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vyndamax (tafamidis 61mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/vyndamax-tafamidis-61mg. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing